Stroke

Ischemic stroke, caused by the disruption of blood flow to the brain, is a devastating condition that affects millions globally each year. As a leading cause of death and disability worldwide, the need for effective therapies to mitigate the damaging effects of ischemic stroke has never been more pressing. At Alfa Cytology, we provide PARP inhibitor development services for the stroke therapy.

PARP as a Therapeutic Target for Stroke

PARP-1, a key enzyme involved in the detection and repair of DNA damage, has emerged as a critical mediator in the cascade of events leading to neuronal cell death following an ischemic insult. The hyperactivation of PARP-1 can trigger a unique form of programmed cell death known as "PARthanatos," which is characterized by extensive DNA fragmentation and mitochondrial dysfunction. Research has shown that the inhibition of PARP-1 activity can effectively reduce infarct size, alleviate inflammation, and improve functional recovery in preclinical models of ischemic stroke. By targeting this crucial pathway, PARP inhibitors hold the potential to provide a much-needed therapeutic option for this devastating condition.

Fig. 1 Emerging role of PARP-1 in ischemic stroke. (Liu S., et al. 2022)

PARP Inhibitor Development for Stroke

Studies have shown that olaparib exhibits significant neuroprotective effects in transient ischemic mice, mainly through the reduction of cerebral infarction and blood-brain barrier damage. These promising preclinical findings provide a strong rationale for further investigation of PARP inhibitors, like olaparib, as a novel therapeutic strategy for the management of ischemic stroke.

Our Services

Alfa Cytology offers a comprehensive suite of services to support the development of PARP inhibitor-based therapies for stroke recovery. Our team of experts is dedicated to providing high-quality, data-driven solutions that accelerate the progress of our clients' research and development efforts.

Our comprehensive services include:

Our Stroke Modeling Services

• Transient middle cerebral artery occlusion (tMCAO)
• Permanent middle cerebral artery occlusion (MCAO)
• Endothelin-1-induced middle cerebral artery occlusion (EMCAO)
• Global brain ischemia
• Hind limb ischemia peripheral model
• Stroke prevention model in Dahl/Salt Sensitive (Dahl/SS) or Stroke-Prone Spontaneously Hypertensive (SHRSP) rats

If you are interested in exploring the transformative potential of PARP inhibitors for stroke recovery, we invite you to reach out to Alfa Cytology. Our team of experts is dedicated to advancing the field of PARP inhibitor therapy and collaborating with our clients to bring innovative and effective treatments to market. To learn more about our services or to discuss a potential partnership, please contact us.

For research use only. Not intended for any clinical use.